Post by CorWave

The 46th ISHLT Annual Meeting was a great opportunity for CorWave to connect and partner with the scientific community as we move forward with our ongoing clinical study and prepare for the pivotal phase. At the Late Breaking Science in Heart Transplantation and MCS, A/Prof Kavitha Muthiah from St Vincent's Health Australia presented the latest insights from CorWave’s First-In-Human (FIH) study: ➡️500 cumulative days of support ➡️Full hemodynamic support and preserved pulsatile flow ➡️All patients successfully bridged to transplant A heartfelt thank you to the St Vincent's Health Australia team for their outstanding partnership, and to all leading experts for the enriching discussions. We look forward to shaping the future of MCS together! #CorWave #ISHLT2026 #HeartFailure #Innovation #MCS #Cardiology ISHLT - International Society for Heart and Lung Transplantation [𝘛𝘩𝘦 𝘊𝘰𝘳𝘞𝘢𝘷𝘦 𝘓𝘝𝘈𝘚 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘶𝘯𝘥𝘦𝘳𝘨𝘰𝘪𝘯𝘨 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯. 𝘐𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝑒 𝑖𝑛 𝑎𝑛𝑦 𝑐𝑜𝑢𝑛𝑡𝑟𝑦.]